Xcovery Holdings

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Ensartinib(Ensacove)
Approved
ALKSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
February 2029 (1)
Ensartinib · EnsacovePhase 1/2Solid Advanced Tumor
Est. primary completion 2029-02-01 · NCT07448116 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 July 2026Filing acceptedEnsartinibChina accepts the marketing application for adjuvant ensartinib in resected ALK-positive NSCLC
China, NMPA · Betta Pharmaceuticals Co. · Source ↗

Financial reports

No financial reports recorded.